Proteomic identification and validation of novel biomarkers for monitoring the early phase of renal transplantation

用于监测肾移植早期的新型生物标志物的蛋白质组学鉴定和验证

• 批准号: G0701382/1
• 负责人: Matthew Welberry Smith
• 金额: $ 30.57万
• 依托单位: University of Leeds
• 依托单位国家: 英国
• 项目类别: Fellowship
• 财政年份: 2008
• 资助国家: 英国
• 起止时间: 2008 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0701382%2F1
• 关键词: Proteomic; identification; validation; novel; biomarkers

The number of people being diagnosed with kidney failure is increasing. The treatments for the most severe forms when the kidneys fail completely are dialysis or a kidney transplant. Transplantation is associated with a better quality of life, greater survival, and is cheaper, saving the NHS more than £490 million per year. However, transplanted kidneys don‘t always work immediately, or they may be rejected. The most common way of finding out that there is a problem is by measuring levels of a substance (creatinine) in the blood and then taking a small piece (biopsy) of the kidney tissue but this has risks, is unpleasant for the patient and may be done too late when too much damage has happened. This project is aimed at finding better biomarkers, that is substances (proteins) which can be measured in a blood or urine sample and give us earlier information about whether the kidney is working properly, and if it isn‘t, help us decide quickly what is going wrong. This would enable us to treat the patient in the best way and prevent loss or misfunctioning of the transplanted kidney, both in the short and longer term.

肾功能衰竭的病因有哪些？当肾脏完全衰竭时，最严重的形式的治疗是透析或肾移植。移植与更好的生活质量，更大的生存率相关，并且更便宜，每年为NHS节省超过4.9亿英镑。然而，移植的肾脏并不总是立即工作，或者它们可能被排斥。发现有问题的最常见方法是通过测量血液中物质（肌酐）的水平，然后取一小块肾组织（活检），但这有风险，对患者来说是不愉快的，并且当发生太多损伤时可能做得太晚。该项目旨在寻找更好的生物标志物，即可以在血液或尿液样本中测量的物质（蛋白质），并为我们提供有关肾脏是否正常工作的早期信息，如果不是，帮助我们快速确定出了什么问题。这将使我们能够以最佳方式治疗患者，并在短期和长期内防止移植肾的损失或功能障碍。